Klotho Neurosciences, Inc.
Klotho Neurosciences, Inc. develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates consist of KLTO-101 for the treatment or prevention of Alzheimer's disease; and KLTO-202, a gene therapy product for treatment and prevention of Lou Gehrig's disease. The company was formerly known as Anew Medical, Inc. and changed it… Read more
Klotho Neurosciences, Inc. (KLTO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.110x
Based on the latest financial reports, Klotho Neurosciences, Inc. (KLTO) has a cash flow conversion efficiency ratio of -0.110x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.09 Million) by net assets ($9.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Klotho Neurosciences, Inc. - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Klotho Neurosciences, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Klotho Neurosciences, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klotho Neurosciences, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Srithai Superware Public Company Limited
BK:SITHAI
|
0.047x |
|
AVOD Kurutulmus Gida ve Tarim Urunleri Sanayi Ticaret AS
IS:AVOD
|
0.117x |
|
Unick Corporation
KQ:011320
|
0.054x |
|
Samick Music I
KO:002450
|
0.017x |
|
Brightrock Gold Corp
PINK:BRGC
|
0.051x |
|
Julien's International Entertainment Group
TWO:6595
|
0.057x |
|
Scilex Holding Company
NASDAQ:SCLX
|
-0.046x |
|
Rodex Fasteners
TWO:5015
|
0.126x |
Annual Cash Flow Conversion Efficiency for Klotho Neurosciences, Inc. (2021–2024)
The table below shows the annual cash flow conversion efficiency of Klotho Neurosciences, Inc. from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.19 Million | $-2.95 Million | -2.486x | -217.99% |
| 2023-12-31 | $571.72K | $-446.92K | -0.782x | -53.74% |
| 2022-12-31 | $1.18 Million | $-599.57K | -0.508x | -83.75% |
| 2021-12-31 | $1.03 Million | $-284.02K | -0.277x | -- |